EFFECTS OF PD149163 ON WORKING MEMORY IN A DELAYED NON-MATCH TO POSITION TASK by Thornton, Jennifer L.
Northern Michigan University
NMU Commons
All NMU Master's Theses Student Works
2012
EFFECTS OF PD149163 ON WORKING
MEMORY IN A DELAYED NON-MATCH TO
POSITION TASK
Jennifer L. Thornton
Northern Michigan University
Follow this and additional works at: https://commons.nmu.edu/theses
This Open Access is brought to you for free and open access by the Student Works at NMU Commons. It has been accepted for inclusion in All NMU
Master's Theses by an authorized administrator of NMU Commons. For more information, please contact kmcdonou@nmu.edu,bsarjean@nmu.edu.
Recommended Citation
Thornton, Jennifer L., "EFFECTS OF PD149163 ON WORKING MEMORY IN A DELAYED NON-MATCH TO POSITION
TASK" (2012). All NMU Master's Theses. 519.
https://commons.nmu.edu/theses/519
 
 
!
!
!
EFFECTS OF PD149163 ON WORKING MEMORY IN A DELAYED NON-MATCH 
TO POSITION TASK 
 
 
By 
 
 
Jennifer L. Thornton 
 
 
 
 
 
 
 
 
 
 
THESIS 
 
 
Submitted to  
Northern Michigan University 
In partial fulfillment of the requirements  
For the degree of  
 
 
MASTER OF SCIENCE IN PSYCHOLOGY 
 
 
Graduate Studies Office 
 
 
2012 
 
  

 
 
 
OLSON LIBRARY 
NORTHERN MICHIGAN UNIVERSITY 
 
 
 
 
THESIS DATA FORM 
 
 
 
 
In order to catalog your thesis properly and enter a record in the OCLC international 
bibliographic data base, Olson Library must have the following requested information to 
distinguish you from others with the same name or similar names and to provide 
appropriate subject access for other researchers. 
 
 
 
 
NAME: 
Thornton, Jennifer Lynn 
 
DATE OF BIRTH: 
May 12, 1986 
 
 
 
i 
 
ABSTRACT 
EFFECTS OF PD149163 ON WORKING MEMORY IN A DELAYED NON-MATCH 
TO POSITION TASK 
 
By 
Jennifer L. Thornton 
Schizophrenia is a chronic and debilitating disorder that affects approximately 1 
percent of the population. Cognitive deficits have been recognized one of the core 
features of schizophrenia, and have also been linked to functional outcome. Working 
memory is among the cognitive deficits observed in patients with schizophrenia and is 
thought to be one of the underlying mechanisms of other cognitive functions.   Current 
antipsychotics mainly address positive symptoms, and do little for negative symptoms or 
cognitive deficits. Neurotensin is a hypotensive peptide that has been implicated as a 
possible antipsychotic mechanism. In preclinical trials, neurotensin agonists have been 
shown to have a pharmacological profile similar to atypical antipsychotic drugs. The 
present study assessed the effects of neurotensin-1 agonist PD149163 (0.0625-0.25 
mg/kg) in a delayed non-match to position working memory task as well as typical 
antipsychotic haloperidol (0.025-0.20 mg/kg), atypical antipsychotic risperidone (0.125-
1.0), atypical antipsychotic clozapine (0.625-5.0 mg/kg) and NMDA antagonist MK-801 
(0.025-0.10). The present study revealed that both typical and atypical antipsychotics, 
haloperidol and risperidone respectively, impair working memory. PD149163 appears to 
be similar to clozapine in that it does not alter percent accuracy. The results of this study 
suggest that PD149163 may be similar clozapine regarding efficacy for working memory 
impairments.  
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INTRODUCTION 
 
 
 
 
Schizophrenia is a chronic and debilitating disorder that affects approximately 1 
percent of the population. Schizophrenia consists of a wide array of symptoms that fall 
into three categories: positive symptoms, negative symptoms and cognitive deficits 
(American Psychiatric Association, 2000; Mueser & Jeste, 2008; Weinberger & Harrison, 
2011).  
Symptoms of Schizophrenia 
Positive Symptoms. Positive symptoms include delusions, auditory 
hallucinations, disorganized speech, and catatonia (American Psychiatric Association, 
2000).  Among the positive symptoms, delusions and auditory hallucinations are most 
common (Weinberger & Harrison, 2011). Delusions occur as beliefs that are implausible 
and not derived from everyday experiences. Hallucinations describe experiences 
involving sensory information that is not present.  Auditory hallucinations often consist 
of distinct voices from that of one’s own thoughts (American Psychiatric Association, 
2000).  
Disorganized thinking has been emphasized as a diagnostic characteristic in the 
DSM-IV.  Disorganized thinking consists of thoughts that are hard to follow, and 
individuals with disorganized thinking tend to jump around from idea to idea. 
Disorganized speech also includes speech that is incomprehensible. Disorganized 
behavior can be apparent in a variety of ways, but oftentimes leads to difficulties 
performing everyday activities (American Psychiatric Association, 2000). Catatonic 
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behavior is a lack of reactivity to the environment. This can also be expressed as rigidity, 
an inability to move on command, or random movement. 
Negative Symptoms. Negative symptoms are symptoms that are absent from 
normal functioning (American Psychiatric Association, 2000).  These symptoms include 
affective flattening, alogia, and avolition. One of the most common negative symptoms is 
affective flattening, where a person experiences and displays a diminished range of 
emotions and emotional responses. Alogia, which is a lack of speech, is characterized by 
short, concise, vacant replies, and the person seems to have a reduction of thoughts, 
which results in less productivity of speech as well as diminished fluency. Avolition is 
characterized by the inability to make and carry out goal-oriented actions.  
Cognitive Deficits in Schizophrenia. Though not a diagnostic criteria in the 
DSM-IV, neurocognitive deficits are another array of symptoms that are central to 
schizophrenia (Gold, 2004; Green 1996; Green, Kern, Braff, & Mintz, 2000; Green, Kern 
& Heaton, 2004). Neurocognitive deficits have been reliably demonstrated in the 
literature. There is a broad range of neurocognitive deficits that can vary in degrees of 
severity. Some of the neurocognitive deficits include verbal and nonverbal memory, 
general intelligence, motor performance, visual and auditory attention, spatial ability, 
executive function, language and interhemispheric tactile-transfer (Heinrichs & 
Zakzanies, 1998).   
Cognitive deficits seem to be stable and are not progressive (Heinrichs & 
Zakzanies, 1998). Reichenberg et al. (2009) found that when compared with normal 
controls, individuals with schizophrenia patients exhibited significant impaired 
neurocognitive performance on verbal ability, verbal declarative memory, visual 
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declarative memory, abstractive-executive function, attention and processing speed, 
simple motor skills and language ability. They were also significantly impaired in many 
of these areas compared to patients with psychotic bipolar disorder, schizoaffective 
disorder and psychotic depressive disorder. Furthermore, they found that 15 percent of 
the schizophrenic patients they studied were considered neuropsychologically normal, 
while 81.9 percent were neuropsychologically impaired. Other literature suggests that 
although there is variability in the magnitude of neurocognitive deficits, the majority of 
schizophrenic patients display neurocognitive impairment in memory, executive function, 
motor function, tactile transfer, attention, general intellectual ability and language 
(Reichenberg & Harvey, 2007).  
Working Memory in Schizophrenia 
 Many studies suggest that working memory is a core feature of neurocognitive 
deficits in schizophrenia (Silver, Feldman, Bilker, & Gur, 2003; Goldman-Rakic, 
Castner, Svensson, Siever, & Williams, 2004; Barch & Ceaser, 2012). Working memory 
is a type of memory that holds small amounts of information, including goal-related 
information, during problem solving.  Working memory consists of a phonological loop 
and a visiospacial pad that briefly store specialized auditory and visual information, 
respectively, in the prefrontal cortex.  Working memory tasks involve a delay component 
where neurons in the prefrontal cortex are stimulated and the information is sustained 
during the delay (Durztewitz, Seamans, & Senjowski, 2000; Goldman & Rosvold, 1970; 
Silver et al., 2003). Because of this delay component, much of the research on working 
memory available uses some variation of a delayed task paradigm. In animal models, 
delayed-non-match-to-position tasks have been used to assess working memory in several 
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studies (Ballard & McAllistar, 1999; Ballard & McAllistar 2000; Gemperle, McAllister, 
& Olpe, 2002; Goldman & Rosvold, 1970). Because working memory is thought to be 
the underlying mechanism in executive function, it is vital for normal functioning.  
Deficits in working memory in schizophrenic patients are linked with functional 
outcomes (Silver et al., 2003; Goldman-Rakic et al., 2004). One of the important aspects 
of functional outcome is employment (Green, 1996). Schizophrenia diagnosis is 
associated with the biggest decrease in employment rates among people with long-term 
mental health issues. Perkins and Rinaldi (1999) report that from 1990 to 1999 
unemployment among people with schizophrenia increased from 88 percent to 96 
percent. These factors suggest that neurocognitive deficits should be a target for 
treatment of schizophrenia (Gold, 2004; Green et al., 2000).  
Dopamine. It is thought that dopamine in the prefrontal cortex plays a critical role 
in working memory function (Aalto, Brück, Laine, Någren, & Rinne, 2005; Abi-Dargham 
et al., 2002; Durstewitz et al., 2000; Goldman-Rakic et al., 2004;  Li, Kellendonk, 
Simpson, Kandel, Gao, 2011; Sawaguchi & Goldman-Rakic, 1991). In monkeys, 
depletion of dopamine in the prefrontal cortex causes impairments in working memory 
(Sawaguchi & Goldman-Rakic, 1991). Wantanabe, Kodama, and Hikosaka (1997) found 
that during working memory tasks in nonhuman primates, there was an increase in 
extracellular dopamine in the dorsolateral prefrontal cortex. Studies done with nonhuman 
primates suggest that working memory is reliant on stimulation of D1 receptors in the 
dorsolateral prefrontal cortex, which are much more abundant than D2 receptors (Abi-
Dargham et al., 2002;  Durstewitz, et al. 2000; Goldman-Rakic et al., 2004). Other 
studies have shown that D1 antagonists injected into the prefrontal cortex impair working 
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memory, and it has also been suggested that there are alterations in D1 dopamine 
receptors in the prefrontal cortex of schizophrenic patients (Goldman-Rakic et al., 2004).  
Dopamine pathways start in the ventral tegmental area and then go to the 
mesocortical and mesolimbic dopamine systems. In schizophrenia, psychotic symptoms 
are associated with over-activity of dopamine in the mesolimbic pathway, and cognitive 
and negative symptoms are associated with hypoactivity of dopamine in the mesocortical 
pathway (Diaz-Mataiz et al., 2005). In working memory tasks, dopaminergic neurons are 
activated in the midbrain and the dopamine levels in the prefrontal cortex increase during 
delay-task performance (Phillips, Ahn, & Floresco, 2004). Blocking dopaminergic 
function in the prefrontal cortex disrupts this performance. Research has indicated that in 
schizophrenic patients, dopamine activity is increased in the mesolimbic pathways, but 
that there is dopamine hypoactivity in the prefrontal cortex (Rubeša, Gudelj & Kubinska, 
2011).   
Glutamate. It has been suggested that there is a hypofunction of NMDA 
receptors in the glutamate pathway impair cognitive functioning in schizophrenia. In 
normal brains, NMDA receptor activation causes the release of GABA, which inhibits 
dopamine release from mesolimbic dopamine neurons. If the NMDA receptors become 
under activated there is no inhibition of dopamine release in the mesolimbic dopamine 
pathway, thus producing overexpression of this dopamine pathway. In the mesocortical 
pathway, deficient NMDA receptor activation reduces dopamine neuron activity, 
resulting in diminished dopamine levels in cerebral cortex.  Subsequently, diminished 
cortical dopamine levels likely impairs working memory function (Rubeša et al., 2011).  
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Studies using the NMDA receptor antagonists ketamine, phencyclidine (PCP), 
and dizocilpine (MK-801) support this hypothesis for NMDA receptors in working 
memory function. This class of drugs is often used in animal models of schizophrenia 
because of their ability to induce effects similar to both positive and negative symptoms 
as well as the cognitive deficits associated with schizophrenia. Their ability to impair 
working memory makes them a useful model for finding treatments with the ability to 
reverse these deficits, but also gives some insight on the possible mechanisms involved 
with working memory impairment in schizophrenia (Green, 2003; Levin, Bettegowda, 
Weaver & Christopher, 1998; Meltzer, Horiguchi, & Massey, 2011).  
Serotonin. Serotonin (5-HT2) receptors may also play a role in cognitive function 
in schizophrenia. Various studies have implicated the role of 5-HT2A receptors in 
mechanisms of actions of hallucinogens (Rubeša et al., 2011). Atypical antipsychotics 
also act as 5-HT2A receptor antagonists, further implicating serotonin’s involvement in 
schizophrenia (Mueser & Jeste, 2008). The 5-HT2A pathway interacts with both the 
glutamate and dopamine pathways in the brain. Meltzer et al. (2011) postulate that that 
the 5-HT2A blockade from atypical antipsychotics is the mechanism behind the ability of 
atypical antipsychotics to reverse the effects of NMDA antagonists better than typical 
antipsychotics. There has also been evidence that 5-HT2A receptor-mediated activation 
may be insufficient in patients with schizophrenia. Other studies indicate that there are 
higher levels of platelet serotonin in individuals with schizophrenia compared to healthy 
individuals (Rubeša et al., 2011).   
 
 
7 
 
History of Schizophrenia  
Emil Kraepelin conceptualized the modern concept of schizophrenia in the early 
20th century. Kraepelin coined the term “dementia praecox,” which was meant to 
emphasize that this type of dementia had an early onset, unlike other types of dementia 
such as Alzheimer’s disease. Kraepelin defined symptoms of dementia praecox as 
chronic and progressive, and identified negative symptoms as the most important feature 
of the disorder (Shean, 2004; Weinberger & Harrison, 2011).  
 Eugene Blueler coined the term schizophrenia. Bleuler admired Kraepelin’s work, 
however he did not think that schizophrenia was inevitably chronic and progressive. Like 
Kraepelin, Bleuler thought that negative symptoms, including fragmented thought, were 
the most important feature of the disorder.  Thus Bleuler renamed dementia praecox as 
“schizophrenia;” ”schiz” meaning fragmenting or splitting, and “phren” meaning mind. 
Schizophrenia eventually became the predominant term used to describe the disorder 
(Mueser & Jeste, 2008; Shean, 2004; Weinberger & Harrison, 2011).  
 John Hughlings-Jackson was one of the first psychiatrists to apply a 
characterization of “positive” and “negative” symptoms toward diagnosing patients with 
schizophrenia. He believed that negative symptoms represented a loss of function, and 
that positive symptoms represented an augmentation of normal function (Weinberger & 
Harrison, 2011). For example, affective flattening is defined as a stunted range of 
emotions, which is a loss of the normal range of emotions.  Hallucinations, on the other 
hand, are present in schizophrenic patients, whereas in normal individuals hallucinations 
are not present.  
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During the years of modern medicine there have been changes in what symptoms 
characterized schizophrenia. For many years the focus was on positive symptoms, 
because these symptoms were easier to assess, and that is what clinicians were able to 
treat (Weinberger & Harrison, 2011). In recent years treatment has shifted from simply 
positive symptoms toward also addressing negative symptoms and cognitive deficits.  
Research is being geared towards new drugs that affect both positive and negative 
symptoms, as well as cognitive deficits.  This shift has also led to incorporating cognitive 
function assessments in clinical drug trials (Gold, 2004).  
Antipsychotic Drugs 
 Typical Antipsychotics.  In 1952, a clinical study was conducted that resulted in 
a paradigm shift in the treatment of schizophrenia – the discovery of the first 
antipsychotic drug chlorpromazine (Delay & Deniker, 1952).. Psychiatrists found that 
chlorpromazine was able to reduce the psychotic symptoms associated with 
schizophrenia. After chlorpromazine was discovered, many other antipsychotic drugs 
were synthesized. This class of drugs became known as typical antipsychotics (also 
called classic antipsychotics or first-generation antipsychotics). Typical antipsychotics 
have a high affinity to block D2 receptors (Green, 2003; Meyer & Simpson, 1997; 
Mailman & Murthy, 2010; Mueser & Jeste, 2008; Shean, 2004).  
Typical antipsychotic drugs cause both mild and severe adverse effects. The 
severe side effects include a menagerie of movement problems, which appear in the first 
few days or first few weeks of use. They consist of extrapyramidal side effects; which are 
Parkinson-like symptoms that include tremor, slowed movements, rigidity, as well as 
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acute dystonic reactions, including akathisia, and restlessness (Meyer & Simpson, 1997; 
Shean, 2004).  
Tardive dyskinesia is the most severe adverse effect caused by typical 
antipsychotic drugs.  Tardive dyskinesia is characterized by involuntary movements that 
usually involve the mouth, face, and tongue, and occurs in about 20-30 percent of 
patients taking typical antipsychotics.  These effects are usually seen after long-term use 
of typical antipsychotics and can last for years, and in some cases are irreversible 
(Bishnoi, Chopra, & Kulkarni, 2007).  All of these movement side effects are thought to 
be caused by blocking dopamine D2 receptors in the basal ganglia (Meyer & Simpson, 
1997; Mailman & Murthy; 2010).  
While effective for their ability to reduce positive symptoms of schizophrenia, the 
extrapyramidal side effects are difficult to live with and are associated with patient 
noncompliance (Meyer & Simpson, 1997; Mueser & Jeste, 2008; Shean, 2004). Another 
problem with typical antipsychotics is that they are ineffective, or only partially effective 
in 25-60 percent of patients (Mailman & Murthy, 2010). Typical antipsychotic drugs also 
do not seem to be effective in treating the negative symptoms or cognitive deficits 
associated with schizophrenia (Meyer & Simpson, 1997). In fact, typical antipsychotics 
can impair or limit improvements in cognitive functioning (Terry et al., 2008; Carli, 
Calcagno, Mainolfi, Mainini, & Invernizzi, 2011; Gemperle, et al. 2003).  Research has 
found that chlorpromazine can cause impairments in learning, encoding and retrieval 
(Terry et al., 2008). Studies have shown that at high doses, haloperidol cannot reverse the 
cognitive impairments induced by NMDA antagonist 3-(R)-2-carboxypiperazin-4-propyl-
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1-phosphonic (Carli et al., 2011). In fact, haloperidol, particularly at high doses, impairs 
most types of memory function (Gemperle et al., 2003).  
Atypical Antipsychotics. The introduction of clozapine changed the 
pharmacology of antipsychotics. Clozapine was originally synthesized in 1958 and was 
structurally derived from tricyclic antidepressants (Meyer & Simpson, 1997). While 
laboratory studies eventually indicated it did not have a high affinity for D2 blockade, 
which was a marker for typical antipsychotic drugs, it was shown to be effective in 
treating schizophrenia in clinical trials. Unlike typical antipsychotics, clozapine did not 
cause extrapyramidal side effects and also showed efficacy in the treatment of negative 
symptoms. Clozapine also showed a response rate of about 30-60 percent; and had a 30 
percent response rate in typical antipsychotic-resistant patients, compared with 4 percent 
for chlorpromazine (Kane, Honigfeld, Singer, & Meltzer, 1988; Meyer & Simpson, 1997; 
Mueser & Jeste, 2008; Shean 2004). McEvoy et al. (2006) found that in patients who had 
previously not responded to atypical antipsychotic medication, clozapine was more 
effective than switching to another newer atypical antipsychotic such as olanzapine, 
quetiapine or risperidone.  Clozapine was approved by the FDA in the United States in 
1990 for treating treatment-resistant schizophrenic patients, nearly 40 years after its 
discovery due to the potential for clozapine to cause serious blood disorders such as 
agranulocytosis, leukopenia, neutropenia, leukocytosis, anaemia, eosinophilia, 
thrombocytopenia and thrombocythaemia (Herceg, Mužinić, & Jukić, 2010). After its 
release, patients were required to have weekly white blood cell counts to monitor for 
these potential side effects (Meyer & Simpson, 1997; Mailman & Murthy, 2010; Mueser 
& Jeste, 2008).  
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Clozapine was the first of a new class of drugs known as atypical antipsychotics 
(second-generation antipsychotics) that was pharmacologically defined as antagonizing 
serotonin 5-HT2 receptors with a greater affinity than antagonizing D2 receptors (Meyer 
& Simpson, 1997; Meltzer, Horiguchi, & Massey, 2011; Mueser & Jeste, 2008). It has 
been suggested that antagonism of 5-HT2 receptors increases dopamine in the prefrontal 
cortex, potentially alleviating negative symptoms and cognitive deficits associated with 
schizophrenia (Mueser & Jeste, 2008). However, the effect of clozapine in treating 
cognitive deficits remains unclear. Some studies have shown that clozapine improves 
cognitive functioning in schizophrenia, while others show that it fails to effect on 
cognitive functioning (Rezvani et al. 2008).  
 Risperidone was the second atypical antipsychotic drug approved for use in the 
United States (Shean, 2004). Risperidone did not have the same adverse effects on white 
blood cells as clozapine (Meyer & Simpson, 1997). Risperidone also appeared to cause 
extrapyramidal side effects if the dose was higher than 8.0 mg/day, however the normal 
dose range is between 0.5-6.0 mg/day, with an average of 4 mg/day (Meltzer & McGurk, 
1999; Meyer & Simpson, 1997; Mueser & Jeste, 2008).  
In a meta-analysis conducted by Houthoofd, Morrens, & Sabbe (2008), 
risperidone was associated with improvements in several cognitive domains such as 
processing speed, attention, learning and memory, and reasoning and problem solving.  
However, no improvement in verbal and nonverbal working memory was found. 
Houthoofd et al. (2008) also found that haloperidol and risperidone had similar effects on 
cognition except for verbal learning and memory, reasoning and problem solving, and 
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verbal fluency for which results were ambivalent, and social cognition for which there 
were no data for comparison.   
 One of the major adverse effects associated with most atypical antipsychotics is 
significant weight gain (Allison et al, 1999). Significant weight gain is defined as an 
increase of seven percent from original weight (Farwell et al., 2004). Typical 
antipsychotics can also cause weight gain, but they do not appear to cause as much 
weight gain as some of the atypical antipsychotics. Drugs that have been shown to cause 
significant weight gain include, but are not limited to haloperidol, risperidone and 
clozapine. Clozapine is associated with the highest weight gain with mean increases of 
4.42kg (Allison, et al., 1999). Twenty five percent of people taking atypical 
antipsychotics experienced significant weight gain, 40 percent of people taking 
olanzapine had significant weight gain and 37 percent of people taking risperidone 
experienced significant weight gain within the first year of treatment (Farwell et al. 
2004).  Obesity is associated with many health risks including metabolic syndrome, type 
2 diabetes, hypertension, coronary artery disease, stroke, sleep apnea, cancers, 
reproductive function, osteoarthritis and liver and gall bladder disease (Kopelman, 2006).  
Neurotensin 
Neurotensin is a hypotensive peptide found in the central nervous system as well 
in the peripheral nervous system. It was isolated from bovine hypothalami by Carraway 
and Leeman (1973). Since then, it has been indicated as a possible new target for 
antipsychotic drugs (Boules, Shaw, Fredrickson, & Richelson, 2007).  
In the peripheral nervous system, neurotensin acts as a paracrine and endocrine 
peptide in digestion and cardiovascular function, and is also believed to have effects on 
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growth hormones affecting normal and cancerous cells (McMahon, Boules, Warrington 
& Richelson,  2002). In the central nervous system, neurotensin has hypothermic effects, 
antinociception effects, stimulates anterior pituitary hormone secretion and modulates 
dopamine neurotransmission (McMahon et al., 2002; Cacéda et al., 2006).  
The neurotensin peptide cannot cross the blood brain barrier, however, there have 
been several analogs, which have been developed that do cross the blood brain barrier 
and deliver neurotensin to the brain (McMahon et al., 2002; Cacéda et al., 2006). 
Concentration levels of neurotensin are highest in the amygdala, lateral septum, bed 
nucleus of the stria terminalis, substantia nigra and the ventral tegmental area (Cacéda et 
al., 2006).  
There are three types of neurotensin receptors: NT1, NT2, and NT3.  Most research 
has focused on the first two types of receptors, and the functional response of NT3 
remains.  The affinity of neurotensin for the NT3 receptor is over 1000 fold weaker than 
for NT1 and NT2 receptors (McMahon et al., 2002). High densities of NT1 and NT2 
receptors have been found in the substantia nigra, the entorhinal cortex, cingulate cortex 
and prefrontal cortex in normal postmortem human brain tissues (Lahti, Cochrane, 
Roberts, Conley, & Tamminga, 1998).  
Neurotensin and dopamine. Research has shown that neurotensin interacts with 
several different neuronal systems in the brain associated with schizophrenia and 
antipsychotic drug effects. These include the dopaminergic, serotonergic, cholinergic and 
noradrenergic systems.  It has been postulated that neurotensin’s interaction with the 
dopaminergic system explains many of the antipsychotic effects of neurotensin analogs 
(McMahon et al., 2002). Neurotensin appears to inhibit dopamine D2 receptor function, 
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through either second messenger pathways or direct receptor-receptor interactions 
between NT1 and D2 receptors (Cacéda et al., 2006). The reduction of D2 activation 
resembles effects seen by typical and atypical antipsychotic drugs, which function as 
antagonists for D2 receptors.  Yet, neurotensin does not induce catalepsy, which is an 
animal model of extrapyramidal side effects related to D2 receptor antagonism.  Further, 
neurotensin prevents haloperidol-induced catalepsy (Cacéda et al., 2006; McMahon et al., 
2002).  
Research on postmortem brains of schizophrenic patients found that there are 
decreased neurotensin receptors in prefrontal cortex, the caudate nucleus and the 
cingulate cortex (Lahti et al., 1998). The neurotensin agonist NT69L has also been found 
to increase extracellular dopamine levels in the medial prefrontal cortex, and neurotensin 
administration has also been shown to increase dopamine levels in the prefrontal cortex 
(Prus, Huang, Li, Dai, & Meltzer, 2007). Petkova-Kirova et al. (2008) found that 
injections of neurotensin into prefrontal cortex produced significant, long lasting, and 
concentration-dependent increase in extracellular release of both dopamine and serotonin. 
Injections of neurotensin into the ventral tegmental area have also been shown to increase 
dopamine in the prefrontal cortex (Sotty et al., 2000). In vivo studies of neurotensin 
showed that neurotensin affects extracellular dopamine regulation by reducing dopamine 
D2 and enhancing D1 receptor sensitivity (Fuxe et al., 1992). Since increased dopamine in 
the prefrontal cortex is associated with working memory function, this suggests that 
neurotensin has the potential to improve working memory deficits (Sotty et al., 2000; 
Sawaguchi & Goldman-Rakic, 1991).  
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Herve et al., (1986) found that neurotensin binding is increased in the prefrontal 
and entorhinal cortices after treatment with antipsychotic drugs. There have also been 
reports that neurotensin concentration levels are lower in the cerebral spinal fluid of 
schizophrenics; however, after administration of antipsychotic drugs, neurotensin 
concentration levels are normalized (Binder, Kinkead, Owens & Nemeroff, 2001). There 
has been some indication that increased neurotensin concentration levels in cerebral 
spinal fluid are associated with improvements in negative symptoms (Sharma, Janikac, 
Bissette & Nemeroff, 1997).  
Behavioral effects of neurotensin. In antipsychotic drug screening tests, 
neurotensin agonists have been shown to have a pharmacological profile similar to 
atypical antipsychotic drugs (Cusack, Boules, Tyler, Fauq, McCormick, & Richelson, 
2000; Boules et al., 2007). Feifel, Melendez, Murray, Tina Tran, Rullan, & Shilling 
(2008) showed the neurotensin-1 receptor agonist PD149163 reduced amphetamine 
induced locomotor activity. The neurotensin agonist NT69L has been shown to reduce 
amphetamine and cocaine induced hyperactivity (Boules et al., 2001). Feifel, Melendez 
and Shilling (2004) showed that acute administration of PD149163 and clozapine were 
able to reverse prepulse inhibition deficits in Brattleboro rats; however, acute 
administration of haloperidol did not exhibit these effects, suggesting that neurotensin 
agonists exhibit effects similar to atypical antipsychotic drugs. The NT1 agonist 
PD149163 was also able to block the prepulse inhibition deficits induced by the 5-HT2A 
agonist and hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane 
hydrochloride (Feifel, Melendez, & Shilling, 2003). Feifel et al. (2011) showed that 
clozapine and PD149163 both facilitated prepulse inhibition in Brown Norway rats, 
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whereas haloperidol did not.  PD149163 does not produce cataleptic effects in rats, which 
is an animal model of extrapyramidal side effects (Holly, Ebrecht, & Prus, 2011).  Holly 
et al. (2011) also found that PD149163 significantly decreased conditioned avoidance 
response. 
In screening models of antipsychotic drug effects, PD149163 has been shown to 
produce behaviors similar to other antipsychotic drugs. Azmi, Norman, Spicer and 
Bennett, (2006) found that when given PD149163, rats were able to discriminate objects 
and were also able to reverse scopolamine-induced deficits in novel object 
discrimination. SR142948A (a neurotensin antagonist) blocked the reversal of 
scopolamine-induced deficits by PD149163.  Another neurotensin antagonist, SR48692, 
was found to increase working memory errors in a food search task looking at spatial 
learning in Long-Evans rats (Tirado-Santiago, Muñoz, Rodríguez-González, & 
Maldonado-Vlaar, 2006). In a trace conditioning with an aversive procedure, PD149163 
showed a dose related dissociation between trace and contextual conditioning, whereas 
SR142948A did not (Grimond-Billa, Norman, Bennett, & Cassaday, 2008). In a study 
looking at the effects of PD149163 on associative learning, Norman, Grimond-Billa, 
Bennet, & Cassaday, (2010) found that PD149163, at the 0.125 mg/kg dose,  reduced 
associative learning. There was some overall reduction in associative learning at the 
0.25mg/kg dose. PD149163 has also been shown to improve social discrimination in 
Brattelboro rats as well as in Long Evans rats. (Feifel, Mexal, Melendez, Liu, 
Goldenberg, & Shilling, 2009). Petrie et al. (2004) found that PD149163 increased Fos 
expression in the prefrontal cortex, suggesting potential alleviation of working memory 
deficits in schizophrenia. 
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RATIONALE 
 
 
 
 
Cognitive deficits have been shown to play a critical role in functional outcome 
for schizophrenic patients (Green, 1996). Of these cognitive deficits it has been suggested 
that working memory impairments might be one of the most critical aspects of these 
cognitive deficits, as it is central in executive functioning and planning (Silver, et al. 
2003). Current antipsychotic drugs do little to alleviate these deficits that play such an 
important role in the ability of schizophrenic patients to live a normal life after the onset 
of symptoms (Meyer & Simpson, 1997). Studies have indicated that neurotensin has 
possible antipsychotic efficacy for treating schizophrenia and that it also might have the 
ability to improve cognitive deficits, or at least not further impair them, which would be 
an improvement as compared to many of the current antipsychotic medications. Since the 
neurotensin peptide cannot cross the blood brain barrier, neurotensin receptor agonists 
and antagonists have been developed (Cacéda et al., 2006). One of these analogs, 
PD149163, is a NT1 receptor agonist. Current research suggests PD149163 has a drug 
profile similar to atypical antipsychotic drugs and that it may be able to improve or not 
further disrupt cognitive deficits (Feifel et al., 2003; Norman et al., 2010; Norman, 
Becket, Spicer, Ashton, Langlois, Bennet, 2008). Working memory is often tested using 
delayed response tasks. An animal model of working memory that has been used in many 
studies is a delayed non-match to position (DNMTP) task (Ballard & McAllistar, 1999; 
Ballard & McAllistar 2000; and Gemperle et al., 2002). Therefore, the present study will 
assess the effects of the neurotensin agonist PD149163 on a DNMTP working memory 
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task and compare it to the typical antipsychotic haloperidol and to the atypical 
antipsychotics risperidone and clozapine. 
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METHODS 
 
 
 
Animals  
 
In this study, twelve male Sprague-Dawley rats (390-480g) were used. The rats 
were housed in a vivarium maintained on a 12-hour light/dark (light on at 06:00) 
schedule and constant temperature of 20-22°C. Rats were individually housed and had 
free access to water. Food was restricted in order to maintain the rats at 85 percent of 
their free-feeding body weights. All procedures were approved by the Institutional 
Animal Care and Use Committee at Northern Michigan University.  
Apparatus 
This experiment used six commercially built rat operant chambers (Med-
Associates, St. Albans. VT). Chambers were made of acrylic and stainless steel and had a 
grid floor with a removable waste pan. The chambers were located in sound attenuating 
cabinets that were equipped with fans for ventilation and noise control. Each chamber 
contained three levers. Two of the levers were located on either side of the food tray. The 
third lever was located on the center of the opposite wall (the back wall). A light was 
located approximately 10 centimeters above the center lever and approximately 2.5 
centimeters below the ceiling. Acrylic partitions were located on each side of the center 
lever. Each partition touched both the ceiling and the grid floor on either side of the 
center lever and extended outward approximately 15 centimeters. A mechanical food 
dispenser dispensed a 45mg dustless food pellet (Bio-Serve, Frenchtown, NJ) into the 
food tray.  
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Drugs  
The drugs tested in this study were the NT1 receptor agonist PD149163 (0.0625, 
0.125, and 0.25mg/kg, sc; Gift from the NIMH Drug Repository, Bethesda, MD), the 
atypical antipsychotic drugs risperidone (0.125, 0.25, 0.05mg/kg, ip; Sigma-Aldrich, St. 
Louis, MO) and clozapine (0.625, 1.25, and 2.5mg/kg, ip; NIMH Drug Repository), the 
typical antipsychotic drug haloperidol (0.025, 0.05, 0.1 mg/kg, ip; Sigma-Aldrich),and 
the non-competitive NMDA receptor antagonist (+)-MK-801 maleate ((5S,10R)-(+)-5-
Methyl-10,11-dihydro -5H-dibenzo[a,d]cyclohepten-5,10-imine maleate, 0.025, 0.05, 
0.01 mg/kg, sc; Sigma-Aldrich). 
Risperidone clozapine and haloperidol were dissolved in water with a few drops 
of 85 percent lactic acid. PD149163 and MK-801 were dissolved in 0.9 percent 
physiological saline. Drugs were prepared for a 1ml/kg injection volume and were 
injected 30 minutes prior to testing either subcutaneously (PD149163 and MK-801) or 
intraperitoneally (risperidone, clozapine, and haloperidol). The order of the drugs for 
each animal was assigned in a quasi-random order to provide a different drug testing 
order for each subject.  
Delayed Non-Match To Position Training  
The first training session was conducted to habituate animals to the operant 
chambers. Animals were placed in the chamber and received a food pellet on a fixed 
interval schedule (60s) of reinforcement. In the second training session, animals were 
presented with one lever and received a food pellet every time the lever was pressed. The 
third training session consisted of alternating the extension of either the left or right 
levers, where presses on either lever resulted in a food pellet when pressed.  
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The fourth training session was the introduction of the center lever on the back 
wall. First, the animals were presented with either the left or the right levers on the front 
wall. After the first lever was pressed, the center lever was presented. Once the center 
lever was pressed, animals were rewarded with a food pellet.  
Errorless Training. The fifth training session was errorless training. For 84 trials 
animals were presented with either a right or left lever, which served as the sample lever. 
After the sample lever was pressed, the center lever was presented and sample lever 
retracted. Once the center lever was pressed, it retracted and then the opposite lever of the 
sample lever extended and pressing it resulted in a food pellet.   
Non-Match To Position Training. After six sessions of errorless training, no 
delay non-match to position training was started. First, either the left or right lever was 
presented. Once the lever was pressed the center lever was then presented and the sample 
lever was retracted. Once animals pressed the center lever it retracted and both the left 
and right levers were immediately extended. In order to receive a food pellet the animal 
had to press the opposite lever of the sample lever. If a correct choice was made, levers 
retracted, a food pellet was given, and the next trial began after five seconds. If an 
incorrect choice was made the levers retracted and a “timeout” occurred.  A timeout 
consisted of retracting both levers and deactivating the house light for 20 seconds. After 
the 20 seconds, the light was activated and the next trial began. 
 0-20 second Delayed Non-Match To Position Training. After consistent high 
accuracy performances (≥90% accuracy) in no delay-non-match-to-position training, a 0-
20 second delay was introduced. This training was the same as the no delay non-match to 
position training, except that after the first lever was pressed there was a 0-20 (0, 2.5, 5, 
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7.5,10, 15 and 20s) second delay presented in random order. Animals were trained on this 
task until they achieved three consecutive sessions at the following criteria: a) at least 80 
percent accuracy on the zero second delay, b) at least 50 percent accuracy on the twenty 
second delay, c) 40-60 percent lever preference and d) fewer than 10 percent trial 
omissions.  
Testing Sessions  
Test sessions were identical to training session, except that longer delays were 
used.  After meeting training criteria, rats were tested with different time delay ranges.  
Based upon these results, randomized delays ranging between 0 – 40 seconds (0, 5, 10, 
15, 20, 30, and 40s) were used.  
For drug testing, each rat was tested using a repeated measures design. The 
animals were tested two days a week with at least 48 hours in between testing doses of 
the same drug, with no training sessions in between. After completing all test sessions for 
a particular drug, rats were given three training sessions with 0-20 second delays, as 
described earlier. After meeting training criteria, test sessions were conducted with a 
different drug. 
Data Analysis  
 This study was a repeated measures design with two independent variables. The 
first independent variable was the drug and the second independent variable was the 
delay. There were five dependent variables, which included percent accuracy, omissions, 
sample latency, center lever press rate and correct choice latency. Percent accuracy was 
calculated by dividing the number of correct trials by the number of trials completed and 
then multiplying by 100. Center lever response rate was calculated by dividing the 
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number of center lever presses by the delay length. Sample latency was the amount of 
time it took the animal to press the sample lever after it was extended.  Correct latency 
was the amount of time it took the animal to make a correct choice after both the left and 
right levers were extended. With the exception of analyses for trial omission, analyses 
were not conducted when animals omitted more than 8 trials for a given delay. If a 
particular animal’s data had to be excluded for more than two doses per drug, that animal 
was excluded from the entire analysis of that drug. A two factor repeated measures 
analysis of variance was used to analyze each dependent variable; percent accuracy, 
center rate, sample latency, and correct latency. A one factor repeated measures analysis 
of variance was used to analyze omissions data and time delay data. Tukey HSD post hoc 
multiple comparisons tests were conducted when appropriate.  Analyses were conducted 
using GB-stat (GB-Stat v10; Dynamic Microsystems, Inc., Silver Spring, MD). 
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RESULTS 
 
 
 
 
Training  
Eleven of the animals met criteria in an average of 29.27 (+/- SEM=0.0935) 
training sessions. One animal was removed from the study during training after failure to 
advance beyond errorless training after 24 sessions. Three animals were removed during 
the course of this study due to poor health.  
Time delay 
 Percent Accuracy.  The percent accuracy data for time delay are shown in figure 
1. Time delay significantly decreased percent accuracy (F[6, 76]=9.77, p<0.0001). Tukey 
post hoc multiple comparisons tests revealed significant decreases in percent accuracy 
between 0 second delay and 20, 30 and 40 second delays. 
Omissions.  The omissions data for time delay can be found in table 1.  There was 
no significant effect of time delay on number of omissions (F[6,76]=1.68, p>0.05).  
Center Lever Response Rate.  The center lever response rate data for time delay 
can be found in table 1. There was a significant effect of time delay on center lever 
response rate (F[6,76]=15.90, p<0.0001). Tukey post hoc multiple comparisons tests 
revealed significant increases in center lever response rate between 0 second delay and 5, 
10, 15, 20, 30 and 40 second delays.  
Sample latency.  The sample latency data for time delay can be found in table 1. 
No significant effect of time delay on sample latency was found (F[6,76]=1.01, p>0.05).  
Correct latency. The correct latency data for time delay can be found in table 1. 
No significant effect of time delay on correct latency (F[6,76]=1.53, p>0.05) was found.  
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Table 1. Mean and standard error of the mean (SEM) of time delay for a) numbers of 
omissions, b) center lever response rate, c) sample latency, and d) correct latency. 
 
Delay 
(s)/Variable 
 0 5 10 15  20 30 40  
Omissions Mean 0.200 0.100 0.200 0.400 0.200 0.400 0.300 
SEM 0.133 0.100 0.200 0.267 0.133 0.221 0.213 
Center Rate Mean 0.581 1.006 1.063 1.013 1.020 1.014 1.036 
SEM 0.042 0.128 0.126 0.108 0.107 1.010 0.109 
Sample 
Latency 
Mean 2.222 1.876 2.027 1.851 1.863 2.044 1.887 
SEM 0.531 0.371 0.508 0.392 0.417 0.432 0.315 
Correct 
Latency 
Mean 2.299 2.068 2.14 2.269 2.193 2.087 2.065 
SEM 0.127 0.107 0.122 0.214 0.107 0.126 0.117 
 
 
Figure 1. Effects of 0-40 second delays on percent accuracy.  Percent accuracy data 
expressed as mean (+/-  [SEM], n=11). ***p<0.001 versus 0 second delay. 
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PD149163 
Percent accuracy. The percent accuracy data for PD149163 are shown in figure 
2, top left panel. A statistically significant main effect was found across delays although 
differences between delays verses 0 second delay were not revealed by Tukey post hoc 
multiple comparisons (F[6,24]=11.33, p<0.001). PD149163 failed to alter percent 
accuracy (F[3,12]=0.87, p>0.05). There was a significant interaction between delay and 
PD149163 (F[18,72]=1.99, p<0.05), however multiple comparisons tests failed to reveal 
statistical differences between doses of PD149163 versus vehicle across each time delay 
(F[18,72]=1.99, p<0.05). 
Omissions. Omissions data for PD149163 are shown in figure 2, top right panel.  
PD149163 had a significant effect on number of omissions (F[3, 24]=8.71, p<0.001). 
Post hoc Tukey multiple comparisons revealed a significant increase in number of 
omissions from vehicle to 0.125 mg/kg, and vehicle to 0.25 mg/kg.   
Center Lever Response Rate. Center lever response rate data for PD149163 are 
shown in figure 2, center left panel. A significant main effect of time delay was found 
(F[6,24]=24.02, p<0.0001). Tukey post hoc multiple comparisons tests revealed that there 
was a significant increase in center lever response rate between 0 second delay and 5, 10, 
15, 20, 30, and 40 second delays. There was no significant main effect of dose 
(F[3,12]=0.41, p>0.05) . There was no significant interaction effect found between 
PD149163 and time delay (F[18,72]=0.62, p>0.05) 
Sample Latency. Sample Latency data for PD149163 are shown in figure 2, 
center right panel. There was no significant main effect of time delay (F[6,24]=1.95, 
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p>0.05.) There was no significant main effect of PD149163 (F[3,12]=3.43, p=0.05). No 
interaction effect between PD149163 and delay was found (F[18, 72]=0.95, p>0.05).  
Correct Latency. Correct latency data for PD149163 are shown in figure 2, 
bottom panel. No significant main effects were found for neither drug dose 
(F[3,12]=1.21, p>0.05) nor time delay (F[6,24]=0.26, p>0.05). There was no significant 
interaction between PD149163 and time delay (F[18,72]=1.18, p>0.05). 
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Figure 2. Effects of the neurotensin-1 receptor agonist PD149163 and time delay 
expressed as mean (+/- SEM) a) percent accuracy, n=5 (top left), b) number of omissions, 
n=9 (top right), c) center rate, n=5 (center left), d) sample latency, n=5 (center right)  and 
e) correct choice latency, n=5 (bottom). *p<0.05, **p<0.0001 versus vehicle.  
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Risperidone 
Percent Accuracy. Percent Accuracy data for risperidone are shown in figure 3, 
top left panel. Due to high numbers of trial omissions, risperidone 1.0 mg/kg was 
excluded from analysis, with the exception of omissions data. A significant main effect of 
time delay on percent accuracy was also found (F[6,42]=10.5, p<0.0001). Tukey post hoc 
multiple comparisons tests revealed a significant decrease in percent accuracy from 0 
second delay to 40 second delay. A significant main effect of risperidone on percent 
accuracy was found, although Tukey post hoc multiple comparisons tests failed to reveal 
differences between doses and vehicle(F[3,21]=7.41, p<0.01). No significant interaction 
effect between risperidone and time delay on percent accuracy was revealed 
(F[18,126]=1.25, p>0.05).  
Omissions. The numbers of omissions for risperidone are shown in figure 3, top 
right panel. Risperidone had a significant effect on number of omissions (F[4, 28]=22.02, 
p<0.0001). Post hoc Tukey multiple comparisons tests revealed a significant increase of 
trial omissions from vehicle to 1.0 mg/kg risperidone.  
Center Lever Response Rate. Center lever response rate data for risperidone are 
shown in figure 3, center left panel. A significant main effect of time delay on center rate 
(F[6,42]=3.80, p<0.01) and a main effect of risperidone on center lever response rate 
(F[3, 21]=6.78, p<0.01) were found, however Tukey post hoc multiple comparisons test 
failed to show differences between doses or time delays. No significant interaction 
between risperidone and time delay on center lever response rate was found 
(F[18,126]=1.34, p>0.05).  
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Sample Latency. Sample latency data for risperidone are shown in figure 3, 
center right panel. No main effect of time delay on sample latency was found 
(F[6,42]=2.06, p>0.05). A significant main effect of risperidone on sample latency was 
found, although Tukey post hoc multiple comparisons tests failed to show differences 
between doses (F[3,21]=17.51, p<0.0001). No significant interaction between risperidone 
and time delay on sample latency was revealed (F[18,126)=1.33, p>0,05).  
 Correct Latency. Correct latency data for risperidone are shown in figure 3, 
bottom panel. There was a significant main effect of time delay on correct latency, 
however Tukey post hoc multiple comparisons failed to show differences between time 
delays (F[6,42]=3.20, p<0.05). A significant main effect of dose on correct latency was 
found, however Tukey post hoc multiple comparisons tests failed to reveal differences 
between doses (F[3,21]=19.52, p<0.0001). A significant interaction between risperidone 
and time delay on correct latency was found (F[18,126]=2.88, p<0.01). Tukey multiple 
comparisons tests revealed increased correct latencies between vehicle and 0.50 mg/kg 
risperidone across all delays. 
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Figure 3. Effects of the atypical antipsychotic risperidone and time delay on the mean 
(+/- SEM) a) percent accuracy, n=8 (top left), b) number of omissions, n=8 (top right), c) 
center rate, n=8 (center left), d) sample latency, n=8 (center right) and e) correct choice 
latency, n=7 (bottom). **p<0.01 versus vehicle.  
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Clozapine 
 Percent Accuracy. Percent accuracy data for clozapine are shown in figure 4, top 
left panel. Due to high numbers of trial omissions, 5.0 mg/kg clozapine was not analyzed 
with the exception of omissions data.  A significant main effect of time delay on percent 
accuracy was found (F[6,60]=18.64, p<0.0001). Tukey post hoc multiple comparisons 
showed a significant decrease in accuracy from 0 second delay to 30 and 40 second 
delays. No main effect of clozapine on percent accuracy was revealed (F[3,30]=2.50, 
p>0.05). There was no interaction between clozapine and time delay on percent accuracy 
(F[18, 180)=0.98, p>0.05). 
Omissions. The numbers of omissions data for clozapine are shown in figure 4, 
top right panel. Clozapine had a significant effect on numbers of omissions 
(F[4,24]=13.07, p<0.0001). Tukey post hoc multiple comparisons tests revealed 
significant increases in number of omissions from vehicle to 5.0 mg/kg clozapine.   
Center Lever Response Rate.  Center lever response rate data for clozapine are 
shown in figure 4, center left panel. A main effect of time delay on center rate was found 
(F[6,60]=32.38, p<0.0001). Tukey post hoc multiple comparisons tests revealed 
increased center lever response rate between 0 second delay and 5, 10, 15, 20, 30 and 40 
second delays. No main effect of clozapine on center lever response rate was found 
(F[3,30]=2.21, p>0.05). A significant interaction between clozapine and time delay on 
center lever response rate was found (F[18,180]=1.84, p<0.05). Tukey post hoc multiple 
comparisons tests revealed increased center lever response rates between vehicle and 
0.625 mg/kg at 15 second delay, vehicle and 1.25 mg/kg at 30 second delay, and vehicle 
and 2.5 mg/kg at 30 second delay.  
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Sample Latency. Sample latency data for clozapine are shown in figure 4, center 
right panel. No main effect of time delay on sample latency was revealed (F[6,60]=0.57, 
p>0.05). There was no main effect of clozapine on sample latency (F[3,30)=0.53, 
p>0.05). No significant interaction between clozapine and time delay on sample latency 
was found (F[18,180]=1.25, p>0.05).  
Correct Latency. Correct latency data for clozapine are shown in figure 4, 
bottom panel. There was no significant main effect of time delay on correct latency 
(F[6,60]=1.55, p>0.05). No significant main effect of clozapine on correct latency was 
found (F[3,30]=0.525,p>0.05). A significant interaction between clozapine and time 
delay on correct latency was found, although Tukey post hoc multiple comparisons failed 
to reveal any differences (F[18,180]=1.83, p<0.05). 
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Figure 4.  Effects of the atypical antipsychotic clozapine and time delay on the mean (+/- 
SEM) a) percent accuracy, n=10 (top left), b) number of omissions, n=7 (top right), c) 
center rate, n=10 (center left), d) sample latency, n=10 (center right) and e) correct choice 
latency, n=10 (bottom). *p<0.05, **p<0.01 versus vehicle.  
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Haloperidol  
 Percent Accuracy. The percent accuracy data for haloperidol are shown in figure 
5, top left panel. Due to high numbers of omissions 0.20 mg/kg was removed from 
analysis with the exception of omissions data. A significant main effect of time delay on 
percent accuracy was found (F[6,36]=18.76, p<0.0001). Tukey post hoc multiple 
comparisons tests revealed a significant decrease in accuracy between 0 second delay and 
30 second delay. There was a significant main effect of haloperidol on percent accuracy, 
although Tukey post hoc multiple comparisons tests failed to reveal differences between 
doses (F[3,18]=4.83, p<0.05). There was no significant interaction between haloperidol 
and time delay on percent accuracy (F[18, 108]=0.70, p>0.05).  
 Omissions. The numbers of omissions data for haloperidol are shown in figure 5, 
top right panel. Haloperidol had a significant effect on number of omissions (F[4, 
24]=9.16, p<0.0001). Post hoc Tukey multiple comparisons revealed a significant 
increase in number of omissions from vehicle to 0.10 mg/kg and vehicle to 0.20 mg/kg 
haloperidol.  
Center Lever Response Rate.  Center lever response rate data for haloperidol are 
shown in figure 5, center left panel. There was no main effect of time delay on center rate 
(F[6,36]=1.90, p>0.05). No main effect of haloperidol on center lever response rate was 
revealed (F[3,18]=2.55, p>0.05). There was no significant interaction between 
haloperidol and time delay on center lever response rate (F[18,108]=1.10, p>0.05). 
Sample Latency. Sample latency data for haloperidol are shown in figure 5, 
center right panel. No main effect of time delay on sample latency (F[6,36]=0.65, 
p>0.05). A main effect of haloperidol on sample latency was found, however Tukey post 
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hoc multiple comparisons tests failed to reveal differences between doses (F[3,18]=4.14, 
p<0.0214). There was no significant interaction between haloperidol and time delay on 
sample latency (F[18,108]=0.87, p>0.05).  
Correct Latency. Correct latency data for haloperidol are shown in figure 5, 
bottom panel. There was no main effect of time delay on correct latency (F[6,36]=0.92, 
p>0.05).There was no significant main effect of haloperidol on correct latency 
(F[2,18]=2.72, p>0.05).  No interaction of haloperidol and time delay on correct latency 
was found (F[18,108]=1.17, p>0.05). 
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Figure 5. Effects of the typical antipsychotic haloperidol and time delay on the mean (+/- 
SEM) a) percent accuracy, n=7 (top left), b) number of omissions, n=7 (top right), c) 
center rate, n=7 (center left), d) sample latency, n=7 (center right) and e) correct choice 
latency, n=7 (bottom). **p<0.01 and ***p<0.001 versus vehicle. 
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MK-801 
Percent Accuracy. Percent accuracy data for MK-801 are shown in figure 6, top 
left panel. Due to high numbers of omissions, data for 0.10 mg/kg MK-801 was not 
analyzed with the exception of omissions data. There was a significant main effect of 
time delay on percent accuracy, although Tukey post hoc multiple comparisons test did 
not find differences between delays (F[6,24]=0.44, p<0.0001). MK-801 had a significant 
main effect on percent accuracy, although Tukey post hoc multiple comparisons did not 
reveal differences between doses (F[2,8]=18.30, p<0.001). No interaction effect between 
MK-801 and time delay on percent accuracy was found (F[12,48]=1.03, p>0.05).   
Omissions.  The numbers of omissions data for MK-801 are shown in figure 6, 
top right panel. MK-801 had a significant effect on number of omissions (F[3, 12]=114.6, 
p<0.0001). Post hoc Tukey multiple comparisons tests revealed a significant increase 
from vehicle to 0.10 mg/kg MK-801.  
Center Lever Response Rate.  Center lever response rate data for MK-801 are 
shown in figure 6, center left panel. A main effect of time delay on center lever response 
rate was found (F[6,24]=24.37, p<0.0001).  Tukey post hoc multiple comparisons tests 
revealed an increase in center lever response rates between 0 second delay and 5, 10, 20, 
30 and 40 second delays. No main effect of MK-801 on center lever response rate was 
revealed (F[2,8]=0.82, p>0.05). There was no significant interaction between MK-801 
and time delay on center lever response rate (F[12,48]=0.47, p>0.05). 
Sample Latency.  Sample latency data for MK-801 are shown in figure 6, center right 
panel. No main effect of time delay on sample latency was observed (F[6,24]=1.50, 
p>0.05). There was no significant main effect of MK-801 on sample latency 
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(F[2,8]=4.08, p>0.05). An interaction effect between MK-801 and time delay on sample 
latency was found (F[12,48]=2.03, p<0.05). Tukey post hoc multiple comparisons tests 
revealed an increase in sample latency from vehicle to 0.05 mg/kg following 30 and 40 
second delays.  
Correct Latency.  Correct latency data for MK-801 are shown in figure 6, bottom panel. 
There was no significant main effect of time delay on correct latency (F[6,24]=0.61, 
p>0.05). No significant main effect of MK-801 on correct latency was observed 
(F[2,8]=1.31, p>0.05). There was no significant interaction effect between MK-801 and 
time delay on correct latency (F[12,48]=1.64, p>0.05).  
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Figure 6. Effects of the NMDA receptor antagonist (+)-MK 801 maleate and time delay 
on the mean (+/- SEM) a) percent accuracy, n=5 (top left), b) number of omissions, n=5 
(top right), c) center rate, n=5 (center left), d) sample latency, n=5 (center right) e) correct 
choice latency, n=5 (bottom) **p<0.01 and ***p<0.001 versus vehicle. 
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DISCUSSION 
 
 
 
 
 The present study was conducted to assess the effects of the neurotensin NT1 
receptor agonist PD149163, antipsychotic drugs risperidone, clozapine, haloperidol, and 
non-competitive NMDA receptor antagonist MK-801 on working memory using a 
delayed-non-match to position task. The present study revealed that time delay 
significantly decreased percent accuracy, especially at longer delays. PD149163 and time 
delay had a significant interaction on percent accuracy; however, there was no main 
effect of PD149163 on working memory.  Risperidone and haloperidol both significantly 
decreased percent accuracy, while clozapine did not have an effect on percent accuracy. 
All drugs significantly increased numbers of omissions, mainly at high doses, with the 
exception of PD149163, which increased numbers of omissions at both medium and high 
doses.    
Percent Accuracy 
PD149163 and time delay had a significant interaction, although multiple 
comparisons failed to reveal where the interaction occurred. However, PD149163 did not 
have a significant main effect of dose on percent accuracy. Even with the exclusion of 
high doses due to high numbers of omissions, risperidone, haloperidol and MK-801 all 
significantly decreased percent accuracy, although post hoc multiple comparisons tests 
failed to reveal at what doses for all cases. Clozapine failed to significantly alter percent 
accuracy. Clozapine’s lack of effect on percent accuracy is consistent with other studies 
that have found clozapine either produces an improvement or has no effect on working 
memory (Gemperle et al., 2003).  These results indicate that PD149163 is most similar to 
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clozapine, as both do not alter percent accuracy, and suggests that PD149163 is a 
potential atypical antipsychotic that does not further impair working memory.  
The present study revealed that both typical and atypical antipsychotics impair working 
memory. While clozapine did not impair working memory and does not cause 
extrapyramidal side effects, it does have the potential to cause serious blood disorders 
such as agranulocytosis, leukopenia, neutropenia, leukocytosis, anaemia, eosinophilia, 
thrombocytopenia and thrombocythaemia, which are potentially fatal (Herceg et al., 
2010).  The National Institute of Mental Health started an initiative called the 
Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) that focuses on stimulating the development of cognition-enhancing drugs 
for the treatment of schizophrenia (Green et al., 2004; Marder & Fenton, 2004; Meyer & 
Simpson, 2007). While the focus is on cognitive enhancing drugs, the development of 
drugs that have no effect on cognition are a step in the right direction. While the ultimate 
goal may be to enhance cognition, finding drugs that do not worsen cognition would be 
an improvement. The results from the present study suggest that PD149163 is a possible 
atypical antipsychotic that does not impair working memory, and also does not appear to 
cause extrapyramidal side effects in preclinical models.  Since the cognitive deficits 
associated with schizophrenia are related to functional outcome it is imperative that these 
deficits are addressed as treatment targets (Green, 1996; Green et al., 2000; Green et al. 
2004; Marder & Fenton, 2004).  
Omissions 
One of the limitations of this study was the inability to test higher doses due to the 
high numbers of omissions. In the present study, PD149163 produced a significant main 
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effect on omissions at the 0.125 mg/kg and 0.25 mg/kg doses. Due to high numbers of 
omissions, four animals were excluded from data analysis, which was more than the 
number of animals excluded for risperidone, clozapine or haloperidol. A possible 
explanation for this could be that the doses for PD149163 were too high for this food-
motivated task. It has been suggested that PD149163 decreases food intake in rats, 
especially at 0.25 mg/kg and higher doses and a lack of appetite could be an explanation 
for the high numbers of omissions since the present study relied on a food motivated task 
(Feifel, Goldenberg, Melendez, & Shilling, 2010; Norman, Grimond-Billa, Bennett, & 
Cassaday, 2010). Norman, Grimond-Billa, Bennett, & Cassaday (2010) found that in an 
appetitive trace conditioning procedure, PD149163 decreased unconditioned stimulus 
responses at 0.25 mg/kg, and inter-trial-interval responses at 0.125 mg/kg and 0.25 
mg/kg. However, the neurotensin antagonist SR142948A increased unconditioned 
responding for food as well as inter-trial-interval responses.  
It is also unlikely that these effects were due to motor side effects. In a study 
conducted by Holly et al. (2010), PD149163, even at doses as high as 8.0 mg/kg, did not 
produce catalepsy in rats. Since there was no significant increase of sample latency, 
center lever press rate, or correct latency, it is reasonable to conclude that omissions were 
due to lack of motivation rather than inability to perform the task. Future studies with 
PD149163 might use working memory tasks that utilize water or other non-food 
motivators, since there appears to be a lack of motivation to work for food. Using a non-
food motivated working memory task may yield more accurate results.  
Risperidone also had a significant effect on number of omissions at the 1.0 mg/kg 
dose. However, unlike PD149163, risperidone also significantly increased sample latency 
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and center lever response rates, suggesting that the reasons behind omissions may be due 
to different mechanisms.  Risperidone (0.5 mg/kg) also produced a significant increase in 
correct latency suggesting that it took the animals longer to make a correct choice 
compared to vehicle. Marston et al. (2009) reported similar effects with risperidone in a 
delayed non-match to position task.  
While lower doses of clozapine did not have a significant effect on number of 
omissions, the highest dose of 5.0 mg/kg did. Although sample latency was not affected, 
clozapine also significantly increased center lever response rate. Clozapine and time 
delay had a significant interaction on correct latency. This suggests that while clozapine 
does not alter working memory, it might take longer for a correct decision to be made.  
Haloperidol also significantly increased the number of omissions at the 0.10 
mg/kg and 0.20 mg/kg doses. Gemperle et al. (2003) found that haloperidol increased the 
number of omissions at higher doses. Haloperidol also significantly increased sample 
latency. However, haloperidol did not significantly increase center lever response rate or 
correct latency. These findings are similar to those reported by Gemperle et al. (2003), 
and suggest that the mechanisms behind omission rates are different than PD149163, 
clozapine or risperidone.  
The NMDA non-competitive antagonist MK-801 significantly increased number 
of omissions at the 0.1 mg/kg dose. Due to the high number of omissions, the high dose 
of MK-801 (0.1 mg/kg) was excluded from the data analysis of percent accuracy, center 
lever response rate, sample latency, and correct latency. Despite the exclusion of the high 
dose of MK-801 (0.1 mg/kg), a main effect of MK-801 revealed a significant decrease in 
percent accuracy. There was also a significant interaction between MK-801 and time 
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delay on sample latency and post hoc multiple comparisons revealed that there was an 
increase in sample latency between vehicle and the 0.05 mg/kg dose following 30 and 40 
second delays. One of the major limitations experienced during testing with MK-801 was 
the small sample size. Other studies using MK-801 have demonstrated working memory 
deficits (MacQueen, Bullard, & Galizio, 2011).  
Time Delay 
Time delay had a significant effect on percent accuracy, and post hoc multiple 
comparisons revealed significant differences between 0 second delay and the 20, 30 and 
40 second delays. This is consistent with the concept that working memory temporarily 
holds goal-related information and involves a delay component where neurons in the 
prefrontal cortex are stimulated and the information is sustained during the delay. 
However, because the prefrontal cortex only temporarily holds the information, longer 
time delays cause the information to fade and percent accuracy decreases because the 
information necessary to complete the task is no longer available (Durztewitz et al., 
2000).  
Time delay had no significant effect on omissions, sample latency or correct 
latency. There was, however, a significant effect of time delay on center lever response 
rate. In this task, during the time delay the center lever remained presented for the 
duration of the time delay. For 0 second delay, as soon as animals pressed the center lever 
the choice levers were presented. During the other delays animals continually pressed the 
center lever until the delay was over. The longer the delay was the animals were less 
likely to continually pressed the lever as they were not immediately being rewarded.  
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Time delays in the present study were similar to those found in other studies 
(Ballard & McAllister, 1999; Ballard & McAllister, 2000; Germperle et al., 2003; 
Marston et al., 2009). Ballard and McAllister (1999) showed that there was a decrease in 
choice accuracy across delays. Gemperle et al. (2003) also showed drug-delay 
interactions with decreased choice accuracy for iloperidone and haloperidol at the highest 
doses; however, there was no dose-delay interaction with clozapine.  Marston et al. 
(2009) reported dose-delay interactions that decreased choice accuracy with olanzapine 
and risperidone at longer delays. Talpos, McTighe, Dias, Saksida, and Bussey (2010) 
compared rats with a hippocampal lesion to controls in a delayed non-match to location 
paradigm. Longer delays decreased accuracy in both controls and lesioned rats. They also 
found that while rats with lesioned hippocampi were able to perform tasks, they were 
more susceptible to delay effects. Béracochéa and Jaffard (1995) also showed time delay 
had a significant effect on accuracy using a delayed non-match to position task using a t 
maze.  
Time delay also had a significant main effect on percent accuracy across testing 
with PD149163, risperidone, clozapine, haloperidol and MK-801. There was no 
significant main effect of time delay on number of omissions across testing with any 
drugs. There was a significant main effect of time delay in testing sessions with 
PD149163, risperidone, clozapine and MK-801, but not haloperidol for center lever 
response rate. The results for the main effect of time delay on center rate during the 
clozapine testing session were identical to the results for center lever response rate for 
time delay with no drugs. There was no main effect of time delay on sample latency 
across testing sessions with PD149163, risperidone, clozapine, haloperidol or MK-801. 
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There was no significant main effect of time delay on correct latency during testing 
sessions with PD149163, clozapine, haloperidol or MK-801. There was, however, a 
significant main effect of time delay on correct latency during testing with risperidone, 
although post hoc Tukey multiple comparisons failed to reveal where the differences 
occurred. With a couple exceptions, overall the main effects of time delay during testing 
sessions was similar to the effects of time delay when no drug was given across all 
dependent variables.   
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CONCLUSION 
 
 
 
 
In conclusion, results for risperidone, clozapine, haloperidol and MK-801 are 
consistent with findings from previous studies; while clozapine had no significant effect 
on working memory, risperidone, haloperidol and MK-801 all reduced accuracy 
(Gemperle, McAllister, & Olpe, 2003; Houthoofd, Morrens, & Sabbe, 2008; MacQueen, 
Bullard, & Galizio, 2011; Rezvani, 2008 ). PD149163 appeared to be similar to clozapine 
in that there was no significant main effect of dose on percent accuracy, however there 
was a significant interaction between dose and time delay with PD149163.  
Due to the high number of omissions at the 0.125 mg/kg and 0.25 mg/kg doses, 
several animals had to be excluded from this study. This exclusion, along with the 
removal of 2 animals from the study resulted in a small sample size, which is a limitation 
of the present study. The doses of PD149163 may have been too high for this food 
motivated task, and one limitation of the present study was the inability to test higher 
doses due to the high number of omissions. Because of the suggested appetite suppressant 
effects of PD149163, using a working memory paradigm that is not a food-motivated 
task, such as a water-motivated task or a light/dark motivated t maze, might yield more 
accurate results (Feifel, Goldenberg, Melendez, & Shilling, 2010; Norman, Grimond-
Billa, Bennett, & Cassaday, 2010). Future studies should consider using non-food 
motivated tasks while testing with neurotensin-1 agonist PD149163. This would help 
with the suggested appetite suppressant effects of PD149163 and allow for higher doses 
to be tested.  
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This is the first study showing the effects of a neurotensin agonist using a delayed 
non-match to position paradigm. The NT1 agonist PD149163 appears to be similar to 
clozapine as neither of these compounds altered percent accuracy, suggesting that NT1 
agonist PD149163 may be no worse than atypical antipsychotic clozapine. There is 
potential for NT1 receptor agonists to be effective antipsychotic drugs that fail to impair 
or limit gains in cognitive function.  
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APPENDIX B 
 
 
 
 
MEDPC CODE FOR TEST PROCEDURE 
 
 
 
 
\Delayed non-match to position  
\ 
\This is the DNMTP procedure w\ to test longer delays of 0, 10, 20, 30, 40, 50 and 60 
seconds 
\August 18, 2009 
\Written by Adam Prus 
\ 
\ 
\Skematic 
\ Input (Output) 
\ 
\      **************************** 
\      *                      1(1)*  
\      *LIGHT (7)                 * 
\      *                      *****     
\  *****                      *     
\  * 2 (4)                    ** PELLET (3) 
\  *                          **  
\  *****                      *                       
\      *                      ***** 
\      *                      3(2)*  
\      *                          * 
\      **************************** 
\ 
\ 
\ 
\ 
\R1=LEFT 
\R2=CENTER 
\R3=RIGHT 
^LEFT=1 
^CENTER=4 
^RIGHT=2 
^PELLET=3 
^HOUSELIGHT=7 
^FAN=15 
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\ 
\ 
\ 
\A=DELAY 
\B=CORRECT TRIALS 1=CORRECT 
\C=LEFT LEVER PREFERENCE CALCULATION 
\D=CENTER PRESSES 
\E=CENTER RATE R/SEC 
\F= 
\G= 
\H=TIME VARIABLES FOR LATENCY 
\H(1)=START TRIAL TIME (FOR LATENCY TO SAMPLE LEVER PRESS) 
\H(2)=CENTER LEVER START TIME 
\H(3)=NONMATCH LEVER START TIME (FOR LATENCY TO PRESSING MATCH 
OR NONMATCH LEVER) 
\H(4)=TOTAL NUMBER OF LEFT LEVER SAMPLE TRIALS (WHERE RIGHT 
LEVER PRESS IS THE NONMATCH LEVER) 
\H(5)=TOTAL NUMBER OF MATCH ERRORS FOR LEFT LEVER SAMPLE 
TRIALS (WHERE LEFT LEVER PRESS WAS THE MATCH LEVER) 
\H(6)= 
\H(7)= 
\H(8)=CENTER LEVER PRESSES 
\I=USED TO ACCESS DELAYS 
\J=USED IN SUMARRAY CALCULATION FOR INCORRECT CHOICE LATENCY 
CALCULATION 
\L=SAMPLE LEVER 1=LEFT 3=RIGHT 
\M=SAMPLE LATENCY (TIME BETWEEN TRIAL START AND SAMPLE PRESS) 
\N=CENTER LATENCY (TIME BETWEEN SAMPLE PRESS AND CENTER PRESS) 
\O=NONMATCH LATENCY-CORRECT (TIME BETWEEN CENTER PRESS AND 
NONMATCH LEVER PRESS) 
\P=ACCESS TO LIST X 
\Q=LATENCY CALCULATIONS; DIM INTO FOUR VARIABLES 
\Q(1)=MEAN FIRST PRESS LATENCY 
\Q(2)=MEAN CENTER PRESS LATENCY 
\Q(3)=MEAN INCORRECT CHOICE LATENCY 
\Q(4)=MEAN CORRECT TRIAL LATENCY 
\Q(5)=MEAN TOTAL TRIAL LATENCY 
\Q(6)=DUMMY LABEL DURING SESSION 
\Q(7)=PERCENT CORRECT TRIALS 
\R=MATCH LATENCY-INCORRECT 
\S=OMISSIONS BY TRIAL (DIM BELOW) 
\U=TRIAL COUNTER 
\V= 
\W= 
\X=LIST FOR RANDOM LEVER CHOICE 
\Y=SECONDS 
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\ 
List X = 0,1 \1=LEFT SAMPLE 0=RIGHT SAMPLE 
LIST W = 0.1",5",10",15",20",30",40" \DELAYS 
VAR_ALIAS MEAN FIRST PRESS LATENCY=Q(1) 
VAR_ALIAS MEAN CENTER LATENCY=Q(2) 
VAR_ALIAS MEAN CORRECT CHOICE LATENCY=Q(3) 
VAR_ALIAS MEAN INCORRECT CHOICE LATENCY=Q(4) 
VAR_ALIAS MEAN TRIAL LATENCY=Q(5) 
DIM A=84 
DIM B=84 
DIM D=84 
DIM E=84 
DIM H=10 \EXPERIMENTAL VARIABLES 
DIM L=84 \SAMPLE LEVER PER TRIAL 
DIM O=84  \CORRECT CHOICE LATENCY 
DIM N=84 \CENTER LATENCY 
DIM M=84 
DIM S=84 \OMISSIONS 
DIM R=84 \INCORRECT CHOICE LATENCY 
DIM Q=6 
\ 
\ 
\ 
\***********************************************************************
***********\ 
\ 
\1. SECONDS (Y) 2. TRIALS (U)  3. DELAY (I)  4.  STATUS  5. LEFT PREF 
\ 
\***********************************************************************
*********** 
\ 
\ 
S.S.1 
S1, 
   #START:ON ^HOUSELIGHT,^FAN;SET P=0, U=0--->S2 
S2, \TRIAL START 
   0.1":ADD U;RANDI P=X;RANDD I=W;SET H(1)=Y, A(U)=I, L(U)=P; SHOW 
2,TRIALS,U, 3,DELAY,I/100; IF P=1 [@LEFT,@RIGHT] \EITHER THE LEFT OR 
RIGHT LEVER PROTRACTS 
       @LEFT: ON ^LEFT--->S3 
       @RIGHT: ON ^RIGHT--->S3 
S3, 
   #R1!#R3:OFF ^LEFT,^RIGHT;ON ^CENTER;SET M(U)=Y-H(1),H(2)=Y;SHOW 
4,CENTER,Q(6)--->S4 
   20":SET S(U)=1;OFF ^LEFT,^RIGHT,^HOUSELIGHT;SHOW 4,TIMEOUT,Q(6)---
>S9 
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S4, 
   I#T:--->S5 
   #R2:ADD H(8)--->SX  
S5, 
   #R2:ADD H(8);SET D(U)=H(8),E(U)=H(8)/(Y-H(2)),H(8)=0;SET H(3)=Y;ON 
^LEFT,^RIGHT;OFF ^CENTER;SHOW 4,CHOICE,Q(6)--->S6 
   20":SET S(U)=1;OFF ^CENTER,^HOUSELIGHT;SHOW 4,TIMEOUT,Q(6)--->S9 
S6, 
   #R1:IF P=1 [@MATCH,@NONMATCH] 
       @MATCH:OFF ^LEFT,^RIGHT,^HOUSELIGHT;SET R(U)=Y-H(3);ADD 
H(4),H(5);SHOW 4, TIMEOUT, Q(6)--->S9 \GO TO TIMEOUT AND ADD 
VARIABLE FOR LEFT LEVER PREFERENCE CALCULATION 
       @NONMATCH:ON ^PELLET; SET B(U)=1,O(U)=Y-H(3); SHOW 4, CORRECT, 
Q(6)--->S7  \CORRECT CHOICE 
   #R3:IF P=0 [@MATCH,@NONMATCH] 
       @MATCH:OFF ^LEFT,^RIGHT,^HOUSELIGHT;SET R(U)=Y-H(3);SHOW 4, 
TIMEOUT,Q(6)--->S9 \GO TO TIMEOUT  
       @NONMATCH:ON ^PELLET; SET B(U)=1,O(U)=Y-H(3);ADD H(4);SHOW 4, 
CORRECT,Q(6)--->S7     \CORRECT CHOICE 
   20":SET S(U)=1;OFF ^LEFT,^RIGHT,^HOUSELIGHT;SHOW 4, TIMEOUT, 
Q(6);IF U>=84 [@STOP, @KEEPGOING] 
       @STOP:SET  C=H(5)/H(4)*100;SHOW 5,LEFT_PREF,C, 6, RIGHT_ERROR 
TRIALS, H(5), 7, RIGHT_TRIALS, H(4)--->STOPABORTFLUSH 
       @KEEPGOING:--->S9 
S7, 
   0.5":OFF ^PELLET,^LEFT,^RIGHT; IF U>=84 [@STOP, @KEEPGOING] 
       @STOP:SET  C=H(5)/H(4)*100;SHOW 5,LEFT_PREF,C, 6, RIGHT_ERROR 
TRIALS, H(5), 7, RIGHT_TRIALS, H(4)--->STOPABORTFLUSH 
       @KEEPGOING:--->S8 
S8, 
    5":--->S2 
S9, 
    20":ON ^HOUSELIGHT;SET P=0;SHOW 3,SAMPLE,Q(6);IF U>=84 [@STOP, 
@KEEPGOING] 
       @STOP:SET  C=H(5)/H(4)*100;SHOW 5,LEFT_PREF,C, 6, RIGHT_ERROR 
TRIALS, H(5), 7, RIGHT_TRIALS, H(4)--->STOPABORTFLUSH 
       @KEEPGOING:--->S2 
 
S.S.2 
S1, 
    #START:--->S2 
S2, 
    0.1":SET Y=Y+0.1; SHOW 1, SECONDS, Y--->SX 
 
